178 related articles for article (PubMed ID: 17878404)
21. Sexual function of adult long-term survivors and their partners after allogeneic hematopoietic cell transplantation in Europe (S-FAST): a study from the Transplant Complications Working Party and Nurses Group of the EBMT.
Gjærde LK; Eeltink C; Stringer J; Mooyaart J; Bosman P; Kenyon M; Liptrott S; Greenfield DM; Linke A; Turlure P; Botti S; Dzaferagic D; Sica S; Welsh L; Kisch A; Perić Z; Schoemans H; Murray J
Bone Marrow Transplant; 2023 Feb; 58(2):195-202. PubMed ID: 36376470
[TBL] [Abstract][Full Text] [Related]
22. Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates.
Nivison-Smith I; Simpson JM; Dodds AJ; Ma DD; Szer J; Bradstock KF
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1323-30. PubMed ID: 19747641
[TBL] [Abstract][Full Text] [Related]
23. A survey of fertility and sexual health following allogeneic haematopoietic stem cell transplantation in New South Wales, Australia.
Dyer G; Gilroy N; Bradford J; Brice L; Kabir M; Greenwood M; Larsen SR; Moore J; Hertzberg M; Kwan J; Brown L; Hogg M; Huang G; Tan J; Ward C; Kerridge I
Br J Haematol; 2016 Feb; 172(4):592-601. PubMed ID: 26847746
[TBL] [Abstract][Full Text] [Related]
24. Fertility and risk factors for elevated infertility concern in 10-year hematopoietic cell transplant survivors and case-matched controls.
Hammond C; Abrams JR; Syrjala KL
J Clin Oncol; 2007 Aug; 25(23):3511-7. PubMed ID: 17646668
[TBL] [Abstract][Full Text] [Related]
25. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
26. Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation.
Bersvendsen HS; Haugnes HS; Dahl AA; Fagerli UM; Fluge Ø; Holte H; Seland M; Wilsgaard T; Smeland KB; Kiserud CE
Bone Marrow Transplant; 2020 May; 55(5):891-905. PubMed ID: 31745250
[TBL] [Abstract][Full Text] [Related]
27. Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors.
Chow EJ; Cushing-Haugen KL; Cheng GS; Boeckh M; Khera N; Lee SJ; Leisenring WM; Martin PJ; Mueller BA; Schwartz SM; Baker KS
J Clin Oncol; 2017 Jan; 35(3):306-313. PubMed ID: 27870568
[TBL] [Abstract][Full Text] [Related]
28. Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34
Scordo M; Shah GL; Kosuri S; Herrera DA; Cho C; Devlin SM; Maloy MA; Nieves J; Borrill T; Avecilla ST; Meagher RC; Carlow DC; O'Reilly RJ; Papadopoulos EB; Jakubowski AA; Koehne G; Gyurkocza B; Castro-Malaspina H; Tamari R; Perales MA; Giralt SA; Shaffer BC
Biol Blood Marrow Transplant; 2018 Jan; 24(1):133-141. PubMed ID: 28870777
[TBL] [Abstract][Full Text] [Related]
29. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
[TBL] [Abstract][Full Text] [Related]
30. Sexual health problems in French cancer survivors 2 years after diagnosis-the national VICAN survey.
Ben Charif A; Bouhnik AD; Courbière B; Rey D; Préau M; Bendiane MK; Peretti-Watel P; Mancini J
J Cancer Surviv; 2016 Jun; 10(3):600-9. PubMed ID: 26685697
[TBL] [Abstract][Full Text] [Related]
31. Changes in sexual functioning in women after neuromodulation for voiding dysfunction.
Yih JM; Killinger KA; Boura JA; Peters KM
J Sex Med; 2013 Oct; 10(10):2477-83. PubMed ID: 23445354
[TBL] [Abstract][Full Text] [Related]
32. Sexual health in long-term breast cancer survivors.
Soldera SV; Ennis M; Lohmann AE; Goodwin PJ
Breast Cancer Res Treat; 2018 Nov; 172(1):159-166. PubMed ID: 30027300
[TBL] [Abstract][Full Text] [Related]
33. Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.
El-Jawahri A; LeBlanc T; VanDusen H; Traeger L; Greer JA; Pirl WF; Jackson VA; Telles J; Rhodes A; Spitzer TR; McAfee S; Chen YA; Lee SS; Temel JS
JAMA; 2016 Nov; 316(20):2094-2103. PubMed ID: 27893130
[TBL] [Abstract][Full Text] [Related]
34. Genomic instability after allogeneic hematopoietic cell transplantation is frequent in oral mucosa, particularly in patients with a history of chronic graft-versus-host disease, and rare in nasal mucosa.
Khan FM; Sy S; Louie P; Ugarte-Torres A; Berka N; Sinclair GD; Stewart DA; Russell JA; Storek J
Blood; 2010 Sep; 116(10):1803-6. PubMed ID: 20548092
[TBL] [Abstract][Full Text] [Related]
35. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
37. Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients.
Bush NE; Donaldson GW; Haberman MH; Dacanay R; Sullivan KM
Biol Blood Marrow Transplant; 2000; 6(5A):576-91. PubMed ID: 11071263
[TBL] [Abstract][Full Text] [Related]
38. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Scott BL; Pasquini MC; Logan BR; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick ED; Fernandez HF; Alyea EP; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Le-Rademacher J; Mendizabal AM; Horowitz MM; Deeg HJ; Horwitz ME
J Clin Oncol; 2017 Apr; 35(11):1154-1161. PubMed ID: 28380315
[TBL] [Abstract][Full Text] [Related]
39. Sexuality, Menopausal Symptoms, and Quality of Life in Premenopausal Women in the First Year Following Hematopoietic Cell Transplantation.
Tierney DK; Palesh O; Johnston L
Oncol Nurs Forum; 2015 Sep; 42(5):488-97. PubMed ID: 26302277
[TBL] [Abstract][Full Text] [Related]
40. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
